Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    A blood test for antibodies will show if you have been exposed to hepatitis C.HIV treatment has particular benefits for people with HIV and hepatitis...

    From: Factsheets

    Information level Level 2
  • Hepatitis C treatment

    Effective treatments are available for hepatitis C. This field is evolving rapidly and standards of care are changing. The newest drugs can cure most people with hepatitis...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    The old standard of care for hepatitis C treatment for all HCV genotypes was pegylated interferon and ribavirin. Interferon works by stimulating immune system activity against HCV. There...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Messi visits Egypt to promote Hepatitis C treatment

    Supported by the Egyptian ministries of tourism and aviation, Prime Pharma started a campaign titled “Tour n’ Cure” to promote tourism treatment in Egypt, with Messi being chosen as ambassador for the campaign worldwide.

    22 February 2017 | Daily News Egypt
  • Deal reduces price of life-saving hepatitis C drugs for Canadians

    Tens of thousands of Canadian patients with mild versions of chronic hepatitis C could soon receive public funding for medications that cure the infection now that the provinces have sealed a deal with three pharmaceutical companies to reduce the cost of the ultra-expensive drugs.

    22 February 2017 | The Globe and Mail
  • SF working on ambitious plan to eliminate hepatitis C

    San Francisco is trying to become the first city in the nation to eliminate hepatitis C, rolling out an ambitious plan that would involve curing everyone who already has it and stopping further spread of the infectious disease, which can cause severe liver damage.

    21 February 2017 | San Francisco Chronicle
  • Hepatitis C will be eradicated in Australia by 2026, researchers predict

    More than 30,000 people were treated for hepatitis C last year, according to a report published by the Kirby Institute at the University of New South Wales. The report found Australia was in a position to eradicate the disease by 2026.

    21 February 2017 | ABC Online
  • HCV eradication in HIV coinfected patients linked to reduced diabetes, chronic renal failure

    Eradication of hepatitis C virus infection among patients coinfected with HIV was associated with reductions in diabetes and chronic renal failure in addition to reduced mortality, HIV progression and liver-related events, according to the results of a Spanish cohort study. These findings led investigators to conclude that HIV coinfected patients should receive HCV therapy regardless of their fibrosis stage.

    31 January 2017 | Healio
  • Report Cites Liver Failure Risk With New Hepatitis C Drugs

    A new report questions the safety of some of the new drugs found to cure hepatitis C, in light of findings of liver failure and injury. But hepatitis C virus (HCV) experts say the findings are inconclusive, should be interpreted with great caution, and should not influence prescribing.

    31 January 2017 | Medscape
  • Final yes from NICE for Gilead’s Epclusa

    The National Institute for Health and Care Excellence has now published final guidance endorsing Epclusa as an option for the treatment of adults with chronic hepatitis C genotype 1-6 infection on the NHS in England and Wales.

    27 January 2017 | Pharma Times
  • Egypt combats hepatitis C epidemic with state-run scheme

    Two-year-old programme treats 1m patients following outbreak sparked by dirty needles.

    23 January 2017 | Financial Times
  • Japan: Hepatitis C drug fakes found in Nara drugstore chain

    Counterfeits of the hepatitis C drug Harvoni have been found at a drugstore chain in Nara Prefecture, the health ministry said Tuesday. Harvoni is sold by a Japanese unit of U.S. pharmaceutical firm Gilead Sciences Inc. The ingredients of the counterfeits are now under examination.

    18 January 2017 | The Japan Times
  • The U.S. Government Should Buy Gilead For $156 Billion To Save Money On Hepatitis C

    The U.S. government could cure most Americans suffering from hepatitis C infections if it simply bought drug maker Gilead Sciences on the stock market rather than purchasing its products in the drug market.

    17 January 2017 | Forbes
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.